These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22884145)

  • 1. Overexpression of catalytic subunit M2 in patients with ovarian cancer.
    Wang LM; Lu FF; Zhang SY; Yao RY; Xing XM; Wei ZM
    Chin Med J (Engl); 2012 Jun; 125(12):2151-6. PubMed ID: 22884145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
    Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
    Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
    Wang P; Wu X; Chen W; Liu J; Wang X
    Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.
    Morikawa T; Hino R; Uozaki H; Maeda D; Ushiku T; Shinozaki A; Sakatani T; Fukayama M
    Hum Pathol; 2010 Dec; 41(12):1742-8. PubMed ID: 20825972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.
    Han P; Lin ZR; Xu LH; Zhong Q; Zhu XF; Liang FY; Cai Q; Huang XM; Zeng MS
    Mol Med Rep; 2015 Jul; 12(1):401-9. PubMed ID: 25695839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
    Fang Z; Gong C; Liu H; Zhang X; Mei L; Song M; Qiu L; Luo S; Zhu Z; Zhang R; Gu H; Chen X
    Biochem Biophys Res Commun; 2015 Aug; 464(2):407-15. PubMed ID: 26093293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.
    Aird KM; Li H; Xin F; Konstantinopoulos PA; Zhang R
    Cell Cycle; 2014; 13(2):199-207. PubMed ID: 24200970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
    Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H
    Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
    Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
    Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of mammaglobin B in epithelial ovarian carcinomas.
    Tassi RA; Bignotti E; Rossi E; Falchetti M; Donzelli C; Calza S; Ravaggi A; Bandiera E; Pecorelli S; Santin AD
    Gynecol Oncol; 2007 Jun; 105(3):578-85. PubMed ID: 17343903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer.
    Zhang M; Wang J; Yao R; Wang L
    Int J Gynecol Cancer; 2013 May; 23(4):659-66. PubMed ID: 23466567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.
    Lee B; Ha SY; Song DH; Lee HW; Cho SY; Park CK
    Gut Liver; 2014 Nov; 8(6):662-8. PubMed ID: 25368754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer.
    Morikawa T; Maeda D; Kume H; Homma Y; Fukayama M
    Histopathology; 2010 Dec; 57(6):885-92. PubMed ID: 21166702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
    Yousef GM; Kyriakopoulou LG; Scorilas A; Fracchioli S; Ghiringhello B; Zarghooni M; Chang A; Diamandis M; Giardina G; Hartwick WJ; Richiardi G; Massobrio M; Diamandis EP; Katsaros D
    Cancer Res; 2001 Nov; 61(21):7811-8. PubMed ID: 11691797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma].
    Wang Y; Yang J; Gao Y; Zhao XL; Li HZ; Yao Z
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):522-8. PubMed ID: 19957553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
    Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer.
    Widschwendter A; Müller HM; Hubalek MM; Wiedemair A; Fiegl H; Goebel G; Mueller-Holzner E; Marth C; Widschwendter M
    Gynecol Oncol; 2004 May; 93(2):407-16. PubMed ID: 15099954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.